JP2009541209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541209A5 JP2009541209A5 JP2009507757A JP2009507757A JP2009541209A5 JP 2009541209 A5 JP2009541209 A5 JP 2009541209A5 JP 2009507757 A JP2009507757 A JP 2009507757A JP 2009507757 A JP2009507757 A JP 2009507757A JP 2009541209 A5 JP2009541209 A5 JP 2009541209A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- formula
- methyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 79
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000004166 bioassay Methods 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 4
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 4
- 230000007883 bronchodilation Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 238000001525 receptor binding assay Methods 0.000 claims description 4
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- QMOVGVNKXUTCQU-UHFFFAOYSA-N (2-phenylphenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 QMOVGVNKXUTCQU-UHFFFAOYSA-N 0.000 claims description 2
- -1 4-{[(R) -2- (3-formylamino-4-hydroxyphenyl) -2-hydroxyethylamino] methyl} -2,5-dimethylphenyl Chemical group 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- GUAXRYUAMUPKGJ-UHFFFAOYSA-N NCC(c(cc1NC=O)ccc1O)OP Chemical compound NCC(c(cc1NC=O)ccc1O)OP GUAXRYUAMUPKGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79470206P | 2006-04-25 | 2006-04-25 | |
| PCT/US2007/009925 WO2007127196A2 (en) | 2006-04-25 | 2007-04-24 | DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541209A JP2009541209A (ja) | 2009-11-26 |
| JP2009541209A5 true JP2009541209A5 (cg-RX-API-DMAC7.html) | 2011-05-19 |
Family
ID=38577470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507757A Pending JP2009541209A (ja) | 2006-04-25 | 2007-04-24 | β２アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニスト活性を有するジアルキルフェニル化合物 |
Country Status (20)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2006023457A1 (en) * | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| TW200811105A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| TW200811104A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
| RS52557B (sr) * | 2008-02-06 | 2013-04-30 | Pulmagen Therapeutics (Synergy) Limited | Jedinjenja |
| SI3210981T1 (sl) | 2009-04-23 | 2019-05-31 | Theravance Respiratory Company, Llc | Diamidne spojine, ki imajo muskarinsko receptorsko antagonistično in beta 2 adrenergično receptorsko agonistično aktivnost |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| US20110020423A1 (en) | 2009-07-22 | 2011-01-27 | Puretech Ventures | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| WO2011081937A1 (en) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
| GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
| US10933020B2 (en) | 2018-09-28 | 2021-03-02 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
| CN114409556B (zh) * | 2022-01-28 | 2024-10-18 | 兰州康鹏威耳化工有限公司 | 一种3,4-二取代-2-氨基苯甲醛的制备方法 |
| CN117924216A (zh) * | 2024-01-12 | 2024-04-26 | 王叔和生物医药(武汉)有限公司 | 一种1-哌啶丙酸的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006635A1 (en) | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| CA2182568A1 (en) | 1994-02-10 | 1995-08-17 | Makoto Takeuchi | Novel carbamate derivative and medicinal composition containing the same |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| US6362371B1 (en) * | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| US6693202B1 (en) | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| EP1685118B1 (en) * | 2003-11-21 | 2009-07-08 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| WO2005087735A1 (en) | 2004-03-11 | 2005-09-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| TWI374883B (en) * | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
| JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| WO2006023457A1 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| TW200811105A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| TW200811104A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
-
2007
- 2007-04-23 TW TW096114175A patent/TW200811105A/zh unknown
- 2007-04-24 PE PE2007000509A patent/PE20080094A1/es not_active Application Discontinuation
- 2007-04-24 BR BRPI0710767-6A patent/BRPI0710767A2/pt not_active IP Right Cessation
- 2007-04-24 AU AU2007243481A patent/AU2007243481A1/en not_active Abandoned
- 2007-04-24 RU RU2008146383/04A patent/RU2008146383A/ru not_active Application Discontinuation
- 2007-04-24 KR KR1020087028589A patent/KR20090005389A/ko not_active Withdrawn
- 2007-04-24 CA CA002650530A patent/CA2650530A1/en not_active Abandoned
- 2007-04-24 US US11/789,300 patent/US7524965B2/en active Active
- 2007-04-24 CN CNA2007800140984A patent/CN101426764A/zh active Pending
- 2007-04-24 EP EP07776093A patent/EP2010489B1/en active Active
- 2007-04-24 MX MX2008013555A patent/MX2008013555A/es active IP Right Grant
- 2007-04-24 WO PCT/US2007/009925 patent/WO2007127196A2/en not_active Ceased
- 2007-04-24 ES ES07776093T patent/ES2391584T3/es active Active
- 2007-04-24 AR ARP070101777A patent/AR060647A1/es unknown
- 2007-04-24 JP JP2009507757A patent/JP2009541209A/ja active Pending
-
2008
- 2008-09-25 IL IL194334A patent/IL194334A0/en unknown
- 2008-10-15 ZA ZA200808817A patent/ZA200808817B/xx unknown
- 2008-10-29 CO CO08115666A patent/CO6140054A2/es unknown
- 2008-10-30 NO NO20084603A patent/NO20084603L/no not_active Application Discontinuation
- 2008-11-14 MA MA31382A patent/MA30556B1/fr unknown
-
2009
- 2009-03-18 US US12/406,283 patent/US7687521B2/en active Active
-
2010
- 2010-02-05 US US12/701,108 patent/US8134006B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541209A5 (cg-RX-API-DMAC7.html) | ||
| RU2008146383A (ru) | ДИАЛКИЛФЕНИЛЬНЫЕ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МУСКАРИНОВЫХ РЕЦЕПТОРОВ | |
| JP2007514662A5 (cg-RX-API-DMAC7.html) | ||
| RU2176145C2 (ru) | Синергическое лечение паркинсонизма | |
| JP3981357B2 (ja) | 第４級アンモニウム化合物および抗ムスカリン剤としてのそれらの使用 | |
| RU2015101032A (ru) | ДИАМИДНЫЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ АНТАГОНИСТА МУСКАРИНОВОГО РЕЦЕПТОРА И АКТИВНОСТЬЮ АГОНИСТА β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| CN1615861A (zh) | （1s，2s）－1－（4－羟基苯基）－2－（4－羟基－4－苯基哌啶－1－基）－1－丙醇甲磺酸盐三水合物 | |
| JP5860895B2 (ja) | ５−メチル−１−（ナフタレン−２−イル）−１ｈ−ピラゾール誘導体 | |
| JP2008195730A5 (cg-RX-API-DMAC7.html) | ||
| WO2007093624A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| JP2005516067A5 (cg-RX-API-DMAC7.html) | ||
| JP2002541104A (ja) | ピロリジン系ケモカイン受容体活性調節剤 | |
| JP2009535340A5 (cg-RX-API-DMAC7.html) | ||
| JP2007509103A5 (cg-RX-API-DMAC7.html) | ||
| JP2009532417A5 (cg-RX-API-DMAC7.html) | ||
| CN1149454A (zh) | 采用神经保护剂治疗耳鸣的方法 | |
| RU2011110745A (ru) | [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1н-индол-3-ил]-метанон как ингибитор триптазы тучных клеток | |
| JPWO2009022687A1 (ja) | フェニル酢酸化合物 | |
| WO2004010942A2 (en) | Substituted heterocyclic compounds as modulators of the ccr5 receptor | |
| JP2007514691A5 (cg-RX-API-DMAC7.html) | ||
| JP2010505865A5 (cg-RX-API-DMAC7.html) | ||
| TWI433838B (zh) | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 | |
| JP5468543B2 (ja) | アセトアミド立体異性体 | |
| KR20140041486A (ko) | Ｓ１ｐ１ 수용체 작용제로서의 신규의 피페리디닐 모노카르복실산 | |
| CA2667041A1 (en) | N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression |